biostudies-literatureNgoi NYLNational Medical Research Council (NMRC)Indian Institute of Science Education and Research MohaliIndian Institute of Science Education and Research Mohali (IISER)AstraZeneca (AstraZeneca PLC)National Medical Research CouncilAstraZenecaPangestu Family Foundation Gynaecological Cancer Research Fund3907-3915https://www.ebi.ac.uk/biostudies/studies/S-EPMC12440240biostudies-literatureUnknown31(18)<h4>Purpose</h4>The optimal treatment of recurrent ovarian clear cell carcinoma (rOCCC) remains unknown. This is the first randomized trial to compare durvalumab with chemotherapy in rOCCC.<h4>Patients and methods</h4>MOCCA is a randomized, phase 2 trial conducted in Singapore, Korea, and Australia. Eligible patients had rOCCC with recurrence after platinum-based chemotherapy, Eastern Cooperative Oncology Group performance status ≤2, and no prior immune checkpoint blockade. Patients were randomly assigned (2:1) to durvalumab (1,500 mg every 4 weeks) or chemotherapy. Patients progressing on chemotherapy were allowed to cross over to durvalumab. The primary outcome was progression-free survival. Secondary outcomes included overall survival, objective response rates, and safety.<h4>Results</hClinical cancer research : an official journal of the American Association for Cancer ResearchDurvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial.PMC12440240CSASI21jun-0003NMRC/MOHIAFCat1/0061/2016Ow SGWChay WYChoi CHLim YWTan TZHeong VLim SEKim KKim HSNgoi NYLKim JWGoh JCTan DSPFriedlander MZhu JLim DGoss GTai BCSun HfalseDurvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial.<h4>Purpose</h4>The optimal treatment of recurrent ovarian clear cell carcinoma (rOCCC) remains unknown. This is the first randomized trial to compare durvalumab with chemotherapy in rOCCC.<h4>Patients and methods</h4>MOCCA is a randomized, phase 2 trial conducted in Singapore, Korea, and Australia. Eligible patients had rOCCC with recurrence after platinum-based chemotherapy, Eastern Cooperative Oncology Group performance status ≤2, and no prior immune checkpoint blockade. Patients were randomly assigned (2:1) to durvalumab (1,500 mg every 4 weeks) or chemotherapy. Patients progressing on chemotherapy were allowed to cross over to durvalumab. The primary outcome was progression-free survival. Secondary outcomes included overall survival, objective response rates, and safety.<h4>Results</h2025-01-01T00:00:00Z2025 Sep2026-06-02T05:26:40.744Z2026-04-14T03:14:12.882ZS-EPMC124402404070539610.1158/1078-0432.CCR-25-0201